Literature DB >> 15096157

Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans.

A M Powell1, S Albert, N Oyama, Y Sakuma-Oyama, B Bhogal, M M Black.   

Abstract

We report a patient with chronic lymphocytic leukaemia who developed paraneoplastic pemphigus (PNP) soon after the initiation of fludarabine therapy. He presented with severe oral and cutaneous erosions. Initially, he had high titres of circulating autoantibodies as detected by indirect immunofluorescence (IF) on multiple epithelial substrates (normal human skin, monkey oesophagus, and rat bladder) and by desmoglein 1 and 3 enzyme-linked immunosorbent assays (ELISAs). His oral erosions have subsequently progressed into unusual hyperplastic papillomatous lesions affecting the inner aspect of lips and buccal mucosae, histologically consistent with pemphigus vegetans. Desmoglein 1 antibodies and IF on rat bladder substrate have become negative after 18 months of therapy. Several agents had been initiated to bring the disease under control originally, but a partial remission was achieved and maintained with mycophenolate mofetil and low-dose prednisolone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096157     DOI: 10.1111/j.1468-3083.2004.00917.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  2 in total

Review 1.  Atypical Clinical and Serological Manifestation of Pemphigus Vegetans: A Case Report and Review of the Literature.

Authors:  Rebecca Mergler; Andreas Kerstan; Enno Schmidt; Matthias Goebeler; Sandrine Benoit
Journal:  Case Rep Dermatol       Date:  2017-04-27

2.  Paraneoplastic pemphigus: a paraneoplastic autoimmune multiorgan syndrome or autoimmune multiorganopathy?

Authors:  Vikram K Mahajan; Vikas Sharma; Pushpinder S Chauhan; Karaninder S Mehta; Anju Lath Sharma; C Abhinav; Gayatri Khatri; Neel Prabha; Saurabh Sharma; Muninder Negi
Journal:  Case Rep Dermatol Med       Date:  2012-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.